The Renal Association seeks to involve its Corporate Members widely in all areas of the Association’s activities of mutual relevance. Contact the Secretary or the Treasurer to discuss this.
Otsuka Pharmaceutical is a global healthcare company, founded in 1921 in Naruto, Japan.Our vision is to continue to be innovative, creative and determined to deliver products that will have a positive impact on the lives of people throughout the world.
Our emphasis on unconventional thinking has resulted in the discovery and development of products to treat mental health disorders; kidney, cardiovascular, gastrointestinal and infectious diseases; and blood-related cancers. The Otsuka philosophy remains ‘Otsuka people creating new products for better health worldwide’.
Otsuka Pharmaceutical has research programmes for several, under-funded, diseases which affect global public health, including tuberculosis. Since 2014 we have launched a new anti-tuberculosis drug, the first for over 40 years as well as the first-ever drug treatment for polycystic kidney disease.
The Otsuka Group of companies employs approximately 47,000 people globally with a presence in over 170 countries.
Vifor Fresenius Medical Care Renal Pharma UK, established in November 2015, is a pharmaceutical company specialising in Nephrology. The company is a joint operation between Vifor Pharma (a company of the Galenica Group) and Fresenius Medical Care.
Vifor Pharma is a world leader in the discovery, development, manufacturing and marketing of pharmaceutical products for the treatment of iron deficiency, and Fresenius Medical Care is the world’s leading provider of dialysis services and products.
Since 2010, Vifor Fresenius Medical Care Renal Pharma has been operating as a common company working in partnership with our customers and supplying our leading brands of intravenous iron and introducing our latest product, a non-calcium, iron based phosphate binder to support renal patient needs.
Our vision is to be the customers’ partner of choice for renal pharmaceuticals and innovative patient-centric solutions. We have a strong pipeline focused on helping improve the lives of the growing numbers of patients around the world who suffer from chronic kidney disease (C.K.D.).